MTST (MetaStat) LT-Debt-to-Total-Asset: 0.00 (As of Feb. 2018)


What is MetaStat LT-Debt-to-Total-Asset?

MetaStat MTST LT-Debt-to-Total-Asset is 0.00 as of Feb. 2018.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. MetaStat's long-term debt to total assests ratio for the quarter that ended in Feb. 2018 was 0.00.

MetaStat's long-term debt to total assets ratio stayed the same from Feb. 2017 (0.00) to Feb. 2018 (0.00).

MetaStat  (OTCPK:MTST) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

MetaStat LT-Debt-to-Total-Asset Related Terms

MetaStat LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for MetaStat's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat LT-Debt-to-Total-Asset Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.15 0.00 0.00 0.00

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MetaStat LT-Debt-to-Total-Asset Calculation

MetaStat's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Feb. 2018 is calculated as

LT Debt to Total Assets (A: Feb. 2018 )=Long-Term Debt & Capital Lease Obligation (A: Feb. 2018 )/Total Assets (A: Feb. 2018 )
=0/0.73
=0.00

MetaStat's Long-Term Debt to Total Asset Ratio for the quarter that ended in Feb. 2018 is calculated as

LT Debt to Total Assets (Q: Feb. 2018 )=Long-Term Debt & Capital Lease Obligation (Q: Feb. 2018 )/Total Assets (Q: Feb. 2018 )
=0/0.73
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
MetaStat (MTST) has a LT-Debt-to-Total-Asset of 0.00 as of Feb. 2018. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on MetaStat and its competitors.
Is MetaStat's LT-Debt-to-Total-Asset too high?
MetaStat's current LT-Debt-to-Total-Asset is 0.00.
How does MetaStat's LT-Debt-to-Total-Asset compare to OBMP and NSPX?
MetaStat's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on MetaStat and its competitors. MetaStat's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For MetaStat (MTST), the current LT-Debt-to-Total-Asset is 0.00 as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.